Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA-PKcs, ATM, and ATR are central kinases in the DNA damage response, responsible for detecting DNA lesions and orchestrating repair through phosphorylation of a broad network of substrates. DNA-PKcs primarily mediates nonhomologous end joining of double-strand breaks, ATM is crucial for the homologous recombination pathway and cell cycle checkpoint activation after ionizing radiation, while ATR responds to a wide spectrum of DNA damage including replication stress. Dysfunction or inhibition of these kinases contributes to cancer susceptibility, neurodevelopmental disorders, and can be exploited therapeutically to sensitize cancer cells to cytotoxic therapies[2][3][4][5][7].
Inhibition of kinase activity leads to impaired DNA repair, sensitizing cancer cells to chemotherapy and radiotherapy[1][7]. Synthetic lethality: Tumor cells deficient in ATM are reliant on DNA-PKcs; inhibition leads to cell death[5]. Checkpoint abrogation: Inhibiting ATM or ATR can prevent cell cycle arrest in response to DNA damage.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA-dependent protein kinase catalytic subunit; Ataxia telangiectasia mutated; ATM and Rad3-related kinase (DNA-PKcs; ATM; ATR).